1196-90-3

Basic information

• Product Name: METHYL 4-BROMO-1-METHYL-1H-PYRROLE-2-CARBOXYLATE
• Synonyms: METHYL 4-BROMO-1-METHYL-1H-PYRROLE-2-CARBOXYLATE;Methyl 4-bromo-1-methylpyrrole-2-carboxylate;methyl 4-bromo-1-methyl-1H-pyrrole-2-carboxylate(SALTDATA: FREE);Methyl 4-broMo-1-Methyl-1H-pyrrole-2-carboxyl;4-Bromo-2-(methoxycarbonyl)-1-methyl-1H-pyrrole;Methyl 4-bromo-N-methyl-2-pyrrolecarboxylate
• CAS NO: 1196-90-3
• Molecular Formula: C₇H₈BrNO₂
• Molecular Weight: 218.05
• Product Categories: Esters;Pyrroles & Indoles;Pyrroles & Indoles
• Mol File: 1196-90-3.mol
• Article Data: 9

Chemical Properties

• Melting Point: 63-65°C
• Boiling Point: 263.1°Cat760mmHg
• Flash Point: 112.9°C
• Appearance: /
• Density: 1.53g/cm³
• Storage Temp.: 2-8°C
• PKA: -10.16±0.70(Predicted)
• CAS DataBase Reference: METHYL 4-BROMO-1-METHYL-1H-PYRROLE-2-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 4-BROMO-1-METHYL-1H-PYRROLE-2-CARBOXYLATE(1196-90-3)
• EPA Substance Registry System: METHYL 4-BROMO-1-METHYL-1H-PYRROLE-2-CARBOXYLATE(1196-90-3)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22
• HazardClass: IRRITANT
• Hazardous Substances Data: 1196-90-3(Hazardous Substances Data)

Usage

General Description

Methyl 4-bromo-1-methyl-1H-pyrrole-2-carboxylate is a chemical compound with the molecular formula C8H8BrNO2. It is a pyrrole derivative with a methyl group and a carboxylate group attached to the nitrogen and carbon atoms, respectively. METHYL 4-BROMO-1-METHYL-1H-PYRROLE-2-CARBOXYLATE is commonly used in organic synthesis and pharmaceutical research as a building block for various bioactive molecules and pharmaceutical intermediates. It has potential applications in the development of new drugs and other biologically active compounds due to its unique structure and reactivity. Additionally, it is important to handle this chemical with care as it is considered a hazardous substance and can pose health risks if not properly managed.

Upstream product

• 934-05-4 methyl 4-bromo-1H-pyrrole-2-carboxylate 
• 74-88-4 methyl iodide 
• 21898-65-7 1-methyl-2-trichloroacetyl-1H-pyrrole 
• 96-54-8 N-Methylpyrrole 
• 124-41-4 sodium methylate 
• 184643-69-4 1-(4-bromo-1-methyl-1H-pyrrol-2-yl)-2,2,2-trichloroethan-1-one 
• 67-56-1 methanol 

Downstream Products

• 126092-96-4 methyl 4-<<(tert-butyloxy)carbonyl>amino>-1-methyl-pyrrole-2-carboxylate 

Relevant articles and documents

Synthesis of N-methylpyrrole and N-methylimidazole amino acids suitable for solid-phase synthesis

New and higher yielding synthetic routes to N-protected N-methylpyrrole and N-methylimidazole amino acids are introduced to circumvent difficulties associated with established schemes. Key steps in each synthesis include copper-mediated cross-coupling reaction to directly install a carbamate-protected 4-amine in the N-methylpyrrole derivative and effective nitration followed by a one-pot reduction/Boc protection of the amine in the synthesis of the N-Me-imidazole amino acid.

Synthesis and DNA binding properties of amide bond-modified analogues related to distamycin

Novel nitro analogues of distamycin which have trans olefins or α-diketo moiety instead of amide bond were synthesized. Their DNA binding properties studies by ethidium displacement assay and MPE footprinting experiments were also described.

NOVEL PYRROLE DERIVATIVES FOR THE TREATMENT OF CANCER

The invention provides a method for the treatment of cancer, which method comprises the general formula (I) wherein R1, R2, R3, R4 and W are as described herein.

PYRROLOBENZODIAZEPINES

A compound of formula (I) or a salt or solvate thereof, wherein the dotted double bond indicates the presence of a single or double bond between C2 and C3; R2 is selected from -H, -OH, =O, =CH2, -CN, -R, OR, halo, dihalo, =CHR, =CHRR', -O- SO2-R, CO2R and COR; R7 is selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR', nitro, Me3Sn and halo; where R and R' are independently selected from optionally substituted C1-7 alkyl, C3-20 heterocyclyl and C5-20 aryl groups; R10 and R11 either together form a double bond, or are selected from H and QRQ respectively, where Q is selected from O, S and NH and RQ is H or C1-7 alkyl or H and SOxM, where x is 2 or 3, and M is a monovalent pharmaceutically acceptable cation; A is selected from (A1), (A2), (A3), (A4) or (A5) where X1 and Y1 are selected from: CH and NH; CH and NMe; N and NMe; CH and S; N and S; N and O; and CH and O, respectively; X2 and Y2 are selected from: CH and NH; CH and NMe; N and NMe; CH and S; N and S; N and O; and CH and O, respectively; Z1 is selected from O and S; Z2 is selected from CH and N; F is selected from a single bond and –(E-F1)m-; each E is independently selected from a single bond, and –C(=O)-NH-; each F1 is independently a C3-20 heteroarylene group; m is 1, 2 or 3; G is selected from hydrogen, C1-4alkyl, -C(=O)-O-C1-4alkyl, -(CH2)n-C3-20 heterocycloalkyl, and –O-(CH2)n-C3-20 heterocycloalkyl group; each n is 0-4; provided that A2 is not A2', where X1 and Y1 of A2' are selected from: CH and NMe; COH and NMe; CH and S; N and NMe; N and S, respectively; and provided that A3 is not A3', where X2 and Y2 of A3' are selected from: CH and NMe; COH and NMe; CH and S; N and NMe; N and S, respectively; B is either a single bond or (B1), where X and Y of B1 are selected from: CH and NMe; COH and NMe; CH and S; N and NMe; N and S, respectively; and R1 is C1-4 alkyl.